Screener
Relmada Therapeutics, Inc. RLMD Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | As of / March 31, | As of |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $5,731,401 | $1,568,944 |
| Accrued expenses | 7,160,233 | 4,861,583 |
| Total current liabilities | 12,891,634 | 6,430,527 |
| Stock appreciation rights | 3,738,583 | 1,060,931 |
| Total liabilities | 16,630,217 | 7,491,458 |
| Commitments and Contingencies (See Note 8) | ||
| Stockholders’ Equity: |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s total current liabilities?
- Relmada Therapeutics, Inc. (RLMD) reported total current liabilities of $12.89M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Relmada Therapeutics, Inc.'s total current liabilities increased by 146.4% year-over-year, from $5.23M to $12.89M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s total current liabilities has grown at a -12.6% compound annual growth rate (CAGR), from $12.6M to $6.43M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Relmada Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude